For example, enhanced expression of FKBP51 can stimulate AR in prostate cancer [229,230] and thus drive malignancy, while as a negative regulator of Akt1 FKBP51 is important for the action of chemotherapeutic agents in pancreatic cancer cells [231]. Here, FKBP4 is linked to prostate carcinoma.